Price
No data yet.
Social Signal Score
Analyst Ratings
15 analystsRevenue
$393.10M+26.56%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Vladimir A. Makatsaria
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 3,300
- Beta
- 0.92
- Country
- GB
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 3.14
Financials
Revenue
$393.10M+26.6%Net Income
$34.30MEBITDA
$54.80MFree Cash Flow
$42.80M+37.4%EPS (diluted)
$0.60Shares Outstanding (diluted)
57.40M+18.4%Operating Expenses
$202.60MCash & Debt
$563.50MReturn of Capital
$0.00Revenue by Segment (annual)
$1.38BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.39B | $-242.50M | $-4.45 |
| 2024 | $1.25B | $63.23M | $1.17 |
| 2023 | $1.15B | $17.55M | $0.33 |
| 2022 | $1.02B | $-86.25M | $-1.61 |
| 2021 | $1.04B | $-135.82M | $-2.68 |
| 2020 | $934.24M | $-348.82M | $-7.06 |
| 2019 | $1.08B | $-157.64M | $-3.22 |
| 2018 | $1.11B | $-189.40M | $-3.91 |
| 2017 | $1.01B | $-25.10M | $-0.52 |
| 2016 | $1.21B | $-62.80M | $-1.29 |
| 2015 | $291.56M | $57.85M | $2.19 |
| 2014 | $282.01M | $54.89M | $2.02 |
| 2013 | $254.32M | $46.36M | $1.68 |
| 2012 | $218.50M | $36.08M | $1.30 |
Valuation
LIVNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70+133.33%Social Signal Score
Mentions (6)
- Newsseekingalpha.com·10d ago·Positive
… The Sleep Apnea Market Opens Up LivaNova PLC is rapidly transitioning into a 'clean compounder' with strong growth prospects and legacy liabilities nearly resolved. LIVN raised 2026 guidance to 9-10% revenue growth and 14% adjusted EPS growth, driven by cardiopulmonary and neuromodulation segments. Oxygenator demand exceeds supply, with LIVN gaining market share and expanding production capacity, while OSA entry is poised for favorable reimbursement tailwinds.
View source ↗ - Newsseekingalpha.com·13d ago·Positive
LivaNova PLC (LIVN) Presents at 2026 UBS Global Healthcare Conference Transcript LivaNova PLC ( LIVN ) 2026 UBS Global Healthcare Conference November 9, 2026 11:00 AM EST Company Participants Alex Shvartsburg - Chief Financial Officer Philip Kowalczyk - Chief Strategy & Corporate Development Officer Conference Call Participants Benjamin Bible Presentation Benjamin Bible Welcome. With me today is Alex Shvartsburg and Philip Kowalczyk, CFO and Head of Strategy and EVP from LivaNova.
View source ↗ - Newsseekingalpha.com·18d ago·Positive
LivaNova PLC (LIVN) Q3 2026 Earnings Call Transcript LivaNova PLC (LIVN) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·18d ago·Positive
LivaNova Q3 Earnings Call Highlights LivaNova NASDAQ: LIVN reported third-quarter 2026 revenue growth of 10% from the prior-year period, driven by double-digit gains in its Cardiopulmonary and epilepsy businesses. The medical technology company raised its full-year revenue and adjusted earnings outlook, citing commercial execution, healthy demand and progress in manufacturing capacity expansion.
View source ↗ - Newszacks.com·18d ago·Positive
LivaNova (LIVN) Surpasses Q3 Earnings and Revenue Estimates LivaNova (LIVN) came out with quarterly earnings of $1.23 per share, beating the Zacks Consensus Estimate of $1.03 per share. This compares to earnings of $1.11 per share a year ago.
View source ↗ - Newsfool.com·73d ago·Negative
LivaNova Director Sells 1,650 Shares for $131,500 The sale was valued at approximately $131,500. The shares traded were equal to 17% of the director's equity stake held directly before the filing.
View source ↗
Earnings
Wed, Feb 24(in 3 months)
Consensus estimate $0.98 per share
Typical surprise +16.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 4$1.23 vs $1.06beat
- Wed, Aug 5$1.26 vs $1.09beat
- Wed, May 6$0.98 vs $0.85beat
- Wed, Feb 25$0.86 vs $0.80beat
- Wed, Nov 5$1.11 vs $0.92beat
- Wed, Aug 6$1.05 vs $0.84beat
Estimates and results for LIVN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by LIVN officers and directors.
- Bought
- —
- Sold
- $1.3m
0 trades
7 trades
- Shvartsburg Alexsold
- Bianchi Francescosold
- Story Brookesold
- Bianchi Francescosold
- Tezel Ahmetsold
- Bianchi Francescosold
- Bianchi Francescosold
93 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in LIVN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
